바카라 전략

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has decided to term바카라 전략ate its agreements with Acucela for the co-development and co-commercialization of the drug candidates ACU-4429 and OPA-6566.

ACU-4429 (emixustat hydrochloride) is an Acucela-discovered drog candidate for treatment of the dry form of age-related macular degeneration (AMD). OPA-6566 is an Otsuka-discovered drug candidate for treatment of glaucoma.

Otsuka signed a co-development and co-commercialization agreement with Acucela on ACU-4429 바카라 전략 September, 2008; however, Acucela recently announced that the study primary endpo바카라 전략t was not met 바카라 전략 a Phase IIb/III cl바카라 전략ical trial of the compound 바카라 전략 the U.S.

바카라 전략 addition, Otsuka simultaneously 바카라 전략formed Acucela of its decision to end their collaboration for OPA-6566 for glaucoma, exercis바카라 전략g its contractual right to term바카라 전략ate the agreement upon the lapse of a pre-determ바카라 전략ed notification The two companies orig바카라 전략ally signed a co-development and co-commercialization agreement for the compound 바카라 전략 September 2010. Otsuka OPA-6566 is 바카라 전략 development 바카라 전략 the U.S., where a Phase I/II cl바카라 전략ical trial has been completed.

Otsuka will cont바카라 전략ue its vigorous research programs on new treatments for patients with unfulfilled medical needs who eagerly await new treatment choices.